Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

1-(2,5-dimethoxyphenyl)-3-(substituted pyrimidine-4-yl)urea compound and preparation and application thereof

A dimethoxyphenyl compound technology, applied in the field of medicinal chemistry, can solve problems such as adverse reactions, inconvenient medication for patients, and toxic and side effects

Active Publication Date: 2018-12-21
WENZHOU MEDICAL UNIV
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Considering that different types of drugs are used in combination, there are often inconveniences to patients, drug interactions or incompatibility, resulting in some toxic side effects or adverse reactions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 1-(2,5-dimethoxyphenyl)-3-(substituted pyrimidine-4-yl)urea compound and preparation and application thereof
  • 1-(2,5-dimethoxyphenyl)-3-(substituted pyrimidine-4-yl)urea compound and preparation and application thereof
  • 1-(2,5-dimethoxyphenyl)-3-(substituted pyrimidine-4-yl)urea compound and preparation and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] The synthesis of embodiment 1 compound

[0029] 1.1 The specific synthetic route of the compound is as follows:

[0030]

[0031] 1.2 Synthesis steps

[0032] a. the synthesis of the first step intermediate product:

[0033] Step 1: Take a dry three-neck reaction bottle and put it into a magnet. Add 4-amino-6-chloropyrimidine (1eq), KI (0.5eq), and dissolve with absolute ethanol (35mL). After heating with stirring for 10 min on a magnetic stirrer, trifluoroacetic acid (200 mL) was added. activation. After about 1 h, substituted aniline (0.8 eq) dissolved in absolute ethanol (15 mL) was added for reaction. Note that it should be added in a dropwise manner to achieve the effect of long-term excess reaction, and the dropping time should be controlled at about 1 hour.

[0034] Step 2: use TLC method to detect the reaction progress and reaction effect. Generally, after 36 hours of reaction, the reaction is almost complete. After the reaction is complete, first spi...

Embodiment 2

[0055] Example 2 compound anti-tumor cell activity

[0056] 2.1 Antitumor activity of compounds tested by MTT method

[0057] This experiment uses the MTT method. The selected normal lung cells were BEAS-2B cells; the selected five non-small cell lung cancer cells included lung adenocarcinoma cell A549 (WT EGFR), lung adenocarcinoma cell PC-9 (EGFR d746-750), lung squamous cell carcinoma Cancer cell H520 (FGFR amplification), large cell lung cancer H1581 (FGFR amplification) and lung squamous cell carcinoma H226 (FGFR amplification / overexpressed EGFR). The above-mentioned cells with logarithmic growth were selected, digested, collected, and counted with a cell counting plate. Next, dilute the counted cells to an appropriate concentration (5*10^4 cells / mL~8*10^4 cells / mL), and add the diluted cell suspension to the 96-well plate at 100 μL per well and remember to set blank control wells containing only medium on the same well plate; after plating overnight, replace with fres...

Embodiment 3

[0060] IC of embodiment 3 compound Y6 and Y13 to five kinds of tumor cells 50 experiment

[0061] 3.1 IC of compounds tested by MTT method 50 value

[0062] According to the results of the toxic effects of all the target compounds on normal lung cells and the results of the inhibitory effects on five NSCLC cell lines, we obtained compound Q10 which has inhibitory effects on all five NSCLC cell lines. We choose this compound, further to do IC 50 experiment. Six concentrations (20 μM, 10 μM, 1.0 μM, 0.50 μM, 0.10 μM and 0.01 μM) were first set for this compound. Then, five non-small cell lung cancer cell lines, including A549 cells, PC-9 cells, H520 cells, H1581 cells and H226 cells, were treated with different concentrations of this compound. Obtain the optical density (OD) value, calculate the inhibition rate, and calculate the IC of this compound by GraphPad Prism 5 software 50 value.

[0063] 3.2 Experimental results

[0064] IC for five cancer cells: A549 cells, PC-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a 1-(2,5-dimethoxyphenyl)-3-(substituted pyrimidine-4-yl)urea compound and preparation and application thereof. The compound has no toxicity function on the proliferation of BEAS-2B cells (lung normal cells), but has certain inhibiting functions on the selected five types of non-small cell lung cancer cell lines, such as A549 cells (WT EGFR), PC-9 cells (EGFRdel E746-A75),H520 cells (FGFR amplification), H1581 cells (FGFR amplification), and H226 cells; the certain anti-tumor activity is realized, and the compound is a relative effective EGFR / FGFR (epidermal growth factor receptor / fibroblast growth factor receptor) inhibitor. The formula is shown in the attached figure.

Description

technical field [0001] The invention relates to the technical field of medicinal chemistry, in particular to a 1-(2,5-dimethoxyphenyl)-3-(6-(substituted anilino)pyrimidin-4-yl)urea EGFR / FGFR double small Molecular inhibitors and their preparation methods and applications. Background technique [0002] Receptor tyrosine kinases (RTKs) are the largest type of enzyme-linked receptors in the human body. There are 58 known RTKs in the human genome. RTKs play a vital role in cell growth, proliferation, migration, and differentiation. From epidermal growth factor receptors (EGFRs), fibroblast growth factor receptors (FGFRs) ), hepatocyte growth factor receptors (hepatocyte growth factor receptors, HGFRs), and platelet-derived growth factor receptors (platelet-derived growth factor receptors, PDGFR) and many other RTKs have been pharmacologically proven to have a positive effect on the expression of related proteins Survival of mutated forms of cancer is critical. Tyrosine kinase...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D239/48A61P35/00A61K31/506
CPCA61P35/00C07D239/48
Inventor 叶发青程冬华韩超潘苏伟潘雅倩谢自新
Owner WENZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com